首页> 美国卫生研究院文献>AMB Express >Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors
【2h】

Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors

机译:一次性生物反应器中HEK293T细胞和Vero细胞的大规模微载体培养

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gene therapy and viral vaccine are becoming attractive therapeutic options for the treatment of different malignant diseases. Viral vector productions are often using static culture vessels and small volume stainless steel bioreactors (SSB). However, the yield of each vessel can be relatively low and multiple vessels often need to be operated simultaneously. This significantly increases labor intensity, production costs, contamination risks, and limits its ability to be scaled up, thus, creating challenges to meet the quantities required once the gene therapy or viral vaccine medicine goes into clinical phases or to market. Single-use bioreactor combining with microcarrier provides a good option for viral vector and vaccine production. The goal of the present studies was to develop the microcarrier bead-to-bead expansion and transfer process for HEK293T cells and Vero cells and scale-up the cultures to 50–200 l single-use bioreactors. Following microcarrier bead-to-bead transfer, the peak cell concentration of HEK293T cells reached 1.5 × 106 cells/ml in XDR-50 bioreactor, whereas Vero cells reached 3.1 × 106 cells/ml and 3.3 × 106 cells/ml in XDR-50 bioreactor and XDR-200 bioreactor, respectively. The average growth rates reached 0.61–0.68/day. The successful microcarrier-based scaleup of these two cell lines in single-use bioreactors demonstrates potential large-scale production capabilities of viral vaccine and vector for current and future vaccines and gene therapy.
机译:基因治疗和病毒疫苗正在成为治疗各种恶性疾病的有吸引力的治疗选择。病毒载体的生产通常使用静态培养皿和小体积不锈钢生物反应器(SSB)。但是,每个容器的产量可能相对较低,并且经常需要同时操作多个容器。这极大地增加了劳动强度,生产成本,污染风险,并限制了其扩大规模的能力,因此,一旦基因治疗或病毒疫苗药物进入临床阶段或推向市场,就难以满足所需的数量。一次性生物反应器与微载体相结合,为病毒载体和疫苗的生产提供了很好的选择。本研究的目的是为HEK293T细胞和Vero细胞开发微载体珠对珠的扩展和转移过程,并将培养物扩大到50-200 l一次性生物反应器。微载体从珠到珠转移后,XDR-50生物反应器中HEK293T细胞的峰值细胞浓度达到1.5 reached×10 6 细胞/ ml,而Vero细胞的血细胞浓度达到3.1×10 6 细胞/ ml和3.3×10 6 细胞/ ml。平均增长率达到每天0.61-0.68。在一次性生物反应器中成功地基于微载体对这两种细胞系进行放大,证明了潜在的大规模生产能力,可用于当前和未来的疫苗和基因治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号